Monitor for any subsequent announcement of a new board appointment, but this departure is routine and unlikely to affect operations or strategy.
ABBV drugs
ABBV drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $286.00entry
- T+1 · 13d ago +3.09%α +1.44% · $294.83
- T+5 · 7d ago +2.76%α +3.35% · $293.89
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AbbVie disclosed that Class II director Jennifer L. Davis resigned from the board effective November 2, 2026, following her appointment as CEO of Align Technology. The resignation is not due to any dispute with AbbVie. This is a routine board departure with no material financial impact.
Key Facts
- Jennifer L. Davis, a Class II director, resigned from AbbVie's board effective November 2, 2026.
- Resignation was due to her recent appointment as CEO of Align Technology, Inc.
- The filing states the resignation is not the result of any dispute or disagreement with AbbVie.
- No replacement was named in the filing.
Financial Impact
No financial impact; a single board member departure with no stated compensation or financial terms.
Risk Factors
- Loss of a board member with relevant industry experience, though the filing indicates no disagreement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-121322 |
| Document: 0001104659-26-121322-index-headers.html | 0001104659-26-121322 |
| Document: 0001104659-26-121322-index.html | 0001104659-26-121322 |
| Document: 0001104659-26-121322.txt | 0001104659-26-121322 |
Track record
22 reports on ABBV
7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
- Nov 2, 202614d ago 8-K Neutral 2/10 Viewing Entry $286.00 Now $294.55 +2.99% settles Dec 2
- Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
- Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
- Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers